$PTCT SEC Filings

Filed On	Filing
16 Oct 2026	Form 4: Schmertzler Michael, Director Sold 2,500 shares ($149K)
13 Oct 2026	Form 4: Boulding Mark Elliott, EXEC. VP AND CLO Received 192 shares by exercise or conversion ($7.57K) · Sold 192 shares ($12.3K)
09 Oct 2026	Form 4: Schmertzler Michael, Director Sold 2,500 shares ($158K)
09 Oct 2026	144
07 Oct 2026	Form 4: Boulding Mark Elliott, EXEC. VP AND CLO Received 1,638 shares by exercise or conversion ($64.6K) · Sold 1,638 shares ($105K) · Received 435 shares by exercise or conversion ($17.1K) · 1 more
07 Oct 2026	144
06 Oct 2026	144
05 Oct 2026	144
02 Oct 2026	Form 4: Steele Glenn Jr Md Phd, Director Received 12,000 shares by exercise or conversion ($135K) · Sold 12,000 shares ($782K)
30 Sep 2026	144
21 Sep 2026	8-K: Regulation FD Disclosure; Other Events WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene th...
18 Sep 2026	Form 4: Schmertzler Michael, Director Sold 10,000 shares ($671K) · Sold 10,000 shares ($679K)
11 Sep 2026	Form 4: Schmertzler Michael, Director Sold 10,000 shares ($678K) · Sold 10,000 shares ($673K)
09 Sep 2026	144
28 Aug 2026	Form 4: Schmertzler Michael, Director Sold 12,500 shares ($912K) · Sold 12,500 shares ($895K)
28 Aug 2026	8-K: Entry into a Material Definitive Agreement
25 Aug 2026	144/A
21 Aug 2026	Form 4: Schmertzler Michael, Director Sold 12,500 shares ($917K) · Sold 12,500 shares ($889K)
19 Aug 2026	Form 4: Boulding Mark Elliott, EXEC. VP AND CLO Received 2,813 shares by exercise or conversion ($72.3K) · Sold 2,813 shares ($204K)
19 Aug 2026	144

Comments